Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.
Andrew Yee, MD, an assistant professor of medicine at Harvard Medical School and a hematologist/oncologist with the Center for Multiple Myeloma at the Massachusetts General Hospital, discusses the utility of isatuximab-irfc (Sarclisa) in relapsed/refractory multiple myeloma.
Isatuximab is an anti-CD38 monoclonal antibody that has shown utility within the multiple myeloma space, says Lee. The more options that are available in the field, the better it is for patients with the disease, adds Lee, as multiple myeloma can be a complicated disease with different types of relapses.
ICARIA-MM was the first randomized phase 3 study to demonstrate the value of adding an anti-CD38 monoclonal antibody to pomalidomide (Pomalyst) and dexamethasone, says Lee. This agent is being utilized within the relapse setting, adds Lee. However, at this time, it is unknown whether there is any specific, clinical difference between this agent and daratumumab (Darzalex). That being said, any scenario where daratumumab can be used, isatuximab is also a viable option, says Lee.
No specific clinical reason exists to choose one over the other, but it is helpful that the field has a phase 3 trial to demonstrate the efficacy of the combination of isatuximab with pomalidomide and dexamethasone, concludes Lee.